Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Algernon Pharmaceuticals (AGN) has been added to the Horizons Psychedelic Stock Index ETF (PSYK)
  • The PSYK  offers direct exposure to North American publicly listed securities in the psychedelics industry
  • Algernon recently announced that it had established a clinical research program for the treatment of stroke focused on AP-188, a known psychedelic compound
  • Algernon is a clinical-stage pharmaceutical development company
  • Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.315 per share

Algernon Pharmaceuticals (AGN) has been added to the Horizons Psychedelic Stock Index ETF (PSYK).

The PSYK  is the world’s first ETF offering direct exposure to North American publicly listed securities that have significant business activities in the psychedelics industry.

The underlying index is the North American Psychedelic Stock Index, which is a proprietary index owned and operated by Horizons ETFs, and Solactive AG is the independent calculation agent for the index.

“On February 1st, 2021, Algernon announced that it had established a clinical research program for the treatment of stroke focused on AP-188 (“N,N-Dimethyltryptamine or DMT”), a known psychedelic compound,” said Christopher J. Moreau CEO of Algernon Pharmaceuticals.

“Being added to the PSYK is a reflection of the important work Algernon has undertaken with its DMT stroke research program and will help bring a further level of awareness to the company among a wide range of investors.”

Algernon is a clinical-stage pharmaceutical development company that investigates safe, approved drugs for new disease applications.

Algernon Pharmaceuticals Inc. (AGN) opened trading at C$0.315 per share.

More From The Market Herald
Featured Video Play Icon

" OpSens (TSX:OPS) announces first SavvyWire procedure in the U.S.

OpSens (OPS) is announcing the first SavvyWire procedure in the U.S.

" Lobe Sciences (CSE:LOBE) incorporates Australian subsidiary for psilocin trials

Lobe Sciences (LOBE) has incorporated its wholly-owned Australian subsidiary to facilitate three or more clinical trials.
Featured Video Play Icon

" Rapid Dose Therapeutics (CSE:DOSE) to supply leading gas and convenience store retailer

Rapid Dose (DOSE) has signed a supplier agreement with a leading gas and convenience store retailer.

" NervGen Pharma (TSXV:NGEN) announces leadership changes

NervGen Pharma Corp. (NGEN) has announced several leadership changes.